Ingersoll Rand Inc.
IR · NYSE
Next quarter
Reports Oct 29, 2026.
Consensus is $0.85 EPS for Sep 2026 across 4 estimates, ranging $0.83 to $0.86.
IR Jun 2026
- 2.50%
- -1.11%
- $0.80
- $0.82
- —
- $2.05B
Reported results
- $2.05B
- 42.10%
- $380.30M
- 18.56%
- $256.80M
- $0.66
Highlights
- Second-quarter revenue was $2,048.8 million, up from $1,887.9 million in the year-ago quarter; no percentage growth rate was provided in the supplied material.
- Net income attributable to Ingersoll Rand was $256.8 million, or $0.66 diluted earnings per share, compared with a $115.3 million loss, or a $0.29 diluted loss per share, in the prior-year quarter.
- Gross profit increased to $862.6 million from $824.9 million, while operating income rose to $380.3 million from $76.4 million.
- The prior-year quarter included $229.7 million of goodwill impairment, $36.1 million of other intangible-asset impairment and a $120.9 million loss on equity-method investments; none of those charges appeared in the current quarter.
- Six-month revenue was $3,896.0 million versus $3,604.7 million in 2025, and six-month net income attributable to Ingersoll Rand was $448.9 million versus $71.2 million.
- The supplied material provides no segment revenue or margin figures, subscriber or unit counts, capex figures, or forward guidance ranges.
Analysis
No consensus figures are available, so the quarter cannot be assessed against analyst expectations. Revenue reached $2,048.8 million, compared with $1,887.9 million a year earlier, continuing the sequential increase from $1.85 billion in the first quarter. Gross profit rose to $862.6 million from $824.9 million, while operating income climbed to $380.3 million from $76.4 million. The major year-over-year earnings improvement was driven less by a disclosed segment mix than by the absence of unusual charges recorded in the prior-year period: the 2025 quarter included $229.7 million of goodwill impairment, $36.1 million of other intangible-asset impairment and a $120.9 million equity-method investment loss. Current-quarter selling and administrative expense was $400.8 million versus $371.2 million, amortization was $102.6 million versus $91.6 million, and interest expense was $63.3 million versus $62.7 million. The filing excerpt does not provide operating-margin percentages or segment drivers.
Guidance
No forward guidance ranges were provided in the supplied material. Management’s filing contains standard forward-looking-statement language and identifies uncertainty around global economic and end-market conditions, international operations, tariffs, raw-material availability, currency movements, acquisitions and restructuring initiatives, but it does not state revenue, earnings, margin, cash-flow, capex or segment targets for the next quarter or full year. Accordingly, there is no prior guide in the supplied material against which to compare a current guide, and no assumptions beyond the listed risk factors can be attributed to management’s outlook.
What drove it
- Revenue growth — Second-quarter revenue was $2,048.8 million versus $1,887.9 million in the prior-year quarter.
- Operating income — Operating income increased to $380.3 million from $76.4 million, aided by the absence of prior-year impairment charges.
- Unusual charges — The prior-year quarter included $229.7 million of goodwill impairment, $36.1 million of other intangible-asset impairment and a $120.9 million equity-method investment loss.
- Operating expenses — Selling and administrative expense rose to $400.8 million from $371.2 million, while amortization increased to $102.6 million from $91.6 million.
Watch items
- Global economic and end-market instability could pressure revenue, liquidity, suppliers and customers.
- Changes in U.S. tariff policy or reciprocal foreign-government tariffs remain uncertain and could affect financial results.
- Large or rapid increases in raw-material and component costs, or reduced availability, could hurt operating results.
- The company cautions that acquisitions, restructuring plans and other cost-saving initiatives may not deliver expected benefits.
